The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors

被引:0
作者
Zamani, Farhad [1 ]
Ajdarkosh, Hossein [1 ]
Safarnezhad-Tameshkel, Fahimeh [1 ]
Azarkeivan, Azita [2 ]
Keyvani, Hossein [1 ]
Naserifar, Farshad [1 ]
Vafaeimanesh, Jamshid [1 ,3 ]
机构
[1] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Tehran, Iran
[2] Blood Transfus Res Ctr, High Inst Res & Educ Transfus Med, Thalassemia Clin, Pediat Hematol Oncol, Tehran, Iran
[3] Qom Univ Med Sci, Gastroenterol & Hepatol Dis Res Ctr, Qom, Iran
关键词
Anaemia; daclatasvir; hepatitis C virus; sofosbuvir; thalassaemia major; ADVANCED LIVER-DISEASE; HCV GENOTYPE 1; VIRUS-INFECTION; PHASE-III; RIBAVIRIN; LEDIPASVIR; COMBINATION; PREVALENCE; CIRRHOSIS; NAIVE;
D O I
10.4103/ijmm.IJMM_18_90
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Context: Patients with thalassaemia arc at risk of infections such as hepatitis C virus (HCV) due to their repeated blood transfusions; meanwhile, the treatment of thalassaemia patients who had developed HCV infection is a controversial issue. Aims: Although the effectiveness of direct-acting anti virals on HCV infection has been confirmed, their side-effects as well as effects on haematological factors due to the resultant need for blood transfusion remain to be further understood. Materials and Methods: In this study, 61 patients with major beta thalassaemia and HCV infection, and who had a history of interferon treatment failure were examined. The patients underwent a 24-week treatment with sofosbuvir (SOF) and daclatasvir (DAC). Sustained virological response 12 was used to assess response to treatment. At the end of the study, the need for blood transfusion and serum terrain was evaluated. Results: About 98.4% of the patients responded to the treatment, and only one patient with genotype 1b did not respond positively. No significant complications necessitating treatment cessation were observed, and all the patients tolerated the treatment well. The level of liver enzymes showed a significant reduction 12 weeks after the treatment. The need for blood transfusions in patients before treatment was averagely 1.595 +/- 0.65 bag per month, in which 1.593 +/- 0.64 bags were received after treatment (P = 0.9). This regimen did not affect the amount of anaemia in patients and did not differentiate the need for blood transfusions. The rate of haemoglobin before treatment was 9.5 +/- 1.42 g/dl, which reached 9.6 +/- 1.6 g/dl after treatment (P = 0.54). Ferritin levels decreased significantly (from 1948.08 +/- 1539.54 to 1315.73 +/- 1207.67 ng/ml) (P = 0.001) in the patients after the treatment. Conclusion: Combination of SOF and DAC is an effective and tolerable treatment regimen without affect on the amount of anaemia in patients and did not differentiate the need for blood transfusions.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 50 条
  • [31] Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C
    D'Ambrosio, Roberta
    Aghemo, Alessio
    Colombo, Massimo
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 473 - 484
  • [32] Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C
    Cuenca-Lopez, Francisca
    Rivero, Antonio
    Rivero-Juarez, Antonio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (01) : 105 - 112
  • [33] Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
    Sulkowski, Mark S.
    Flamm, Steve
    Kayali, Zeid
    Lawitz, Eric J.
    Kwo, Paul
    McPhee, Fiona
    Torbeyns, Anne
    Hughes, Eric A.
    Swenson, Eugene S.
    Yin, Philip D.
    Linaberry, Misti
    LIVER INTERNATIONAL, 2017, 37 (06) : 836 - 842
  • [34] The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3
    Merat, Shahin
    Sharifi, Amir Houshang
    Haj-Sheykholeslami, Arghavan
    Poustchi, Hossein
    Fattahi, Babak
    Nateghi-Baygi, Alireza
    Alavian, Seyed Moayed
    Malekzadeh, Reza
    HEPATITIS MONTHLY, 2017, 17 (01) : 1 - 4
  • [35] Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
    Yan Xue
    Li-Xin Zhang
    Lei Wang
    Tao Li
    Yun-Dong Qu
    Feng Liu
    World Journal of Gastroenterology, 2017, (32) : 5969 - 5976
  • [36] Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C
    Carlos del Rio-Valencia, Juan
    Asensi-Diez, Rocio
    Tamayo-Bermejo, Rocio
    Munoz-Castillo, Isabel
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (04) : 296 - 302
  • [37] Efficacy and tolerability of sofosbuvir and daclatasvir for treatment of hepatitis C genotype 1 & 3 in patients undergoing hemodialysis- a prospective interventional clinical trial
    Cheema, Shafiq Ur Rehman
    Rehman, Muhammad Salman
    Hussain, Ghulam
    Cheema, Sidra Shafiq
    Gilani, Nooman
    BMC NEPHROLOGY, 2019, 20 (01)
  • [38] BARCOS (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin
    Ridruejo, Ezequiel
    Cheinquer, Hugo
    Marciano, Sebastian
    Mendizabal, Manuel
    Pinero, Federico
    Wolff, Fernando H.
    de Araujo, Alexandre
    Coelho Borges, Silvia
    Kliemann, Dimas
    Fleck, Alfeu
    de Maman, Italo, Jr.
    Nader, Lysandro A.
    Garrastazul, Patricia
    Bermudez, Carla
    Haddad, Leila
    Gadano, Adrian
    Silva, Marcelo
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (10) : 1200 - 1209
  • [39] End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
    Rahman, Attiya S.
    Amir, Muhammad
    Jamal, Qaiser
    Riaz, Mehwish
    Fareed, Komal
    Siddiqui, Muhammad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
  • [40] Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis
    Buti, M.
    Dominguez-Hernandez, R.
    Oyaguez, I.
    Casado, M. A.
    Esteban, R.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (09) : 750 - 758